AIM: The exact pathomechanism of GNE myopathy remains elusive, but likely involves aberrant sialylation. We explored sialylation status of blood-based glycans as potential disease markers. METHODS: We employed immunoblotting, lectin histochemistry and mass spectrometry. RESULTS: GNE myopathy muscle showed hyposialylation of predominantly O-linked glycans. The O-linked glycome of patients' plasma compared with controls showed increased amounts of desialylated Thomsen-Friedenreich (T)-antigen, and/or decreased amounts of its sialylated form, ST-antigen. Importantly, all patients had increased T/ST ratios compared with controls. These ratios were normalized in a patient treated with intravenous immunoglobulins as a source of sialic acid. DISCUSSION: GNE myopathy clinical trial data will reveal whether T/ST ratios correlate to muscle function. CONCLUSION: Plasma T/ST ratios are a robust blood-based biomarker for GNE myopathy, and may also help explain the pathology and course of the disease.
AIM: The exact pathomechanism of GNE myopathy remains elusive, but likely involves aberrant sialylation. We explored sialylation status of blood-based glycans as potential disease markers. METHODS: We employed immunoblotting, lectin histochemistry and mass spectrometry. RESULTS:GNE myopathy muscle showed hyposialylation of predominantly O-linked glycans. The O-linked glycome of patients' plasma compared with controls showed increased amounts of desialylated Thomsen-Friedenreich (T)-antigen, and/or decreased amounts of its sialylated form, ST-antigen. Importantly, all patients had increased T/STratios compared with controls. These ratios were normalized in a patient treated with intravenous immunoglobulins as a source of sialic acid. DISCUSSION: GNE myopathy clinical trial data will reveal whether T/STratios correlate to muscle function. CONCLUSION: Plasma T/STratios are a robust blood-based biomarker for GNE myopathy, and may also help explain the pathology and course of the disease.
Authors: A Harduin-Lepers; V Vallejo-Ruiz; M A Krzewinski-Recchi; B Samyn-Petit; S Julien; P Delannoy Journal: Biochimie Date: 2001-08 Impact factor: 4.079
Authors: Martina Schwarzkopf; Klaus-Peter Knobeloch; Elvira Rohde; Stephan Hinderlich; Nicola Wiechens; Lothar Lucka; Ivan Horak; Werner Reutter; Rüdiger Horstkorte Journal: Proc Natl Acad Sci U S A Date: 2002-04-02 Impact factor: 11.205
Authors: I Eisenberg; N Avidan; T Potikha; H Hochner; M Chen; T Olender; M Barash; M Shemesh; M Sadeh; G Grabov-Nardini; I Shmilevich; A Friedmann; G Karpati; W G Bradley; L Baumbach; D Lancet; E B Asher; J S Beckmann; Z Argov; S Mitrani-Rosenbaum Journal: Nat Genet Date: 2001-09 Impact factor: 38.330
Authors: Marjan Huizing; Goran Rakocevic; Susan E Sparks; Ioanna Mamali; Alexey Shatunov; Lev Goldfarb; Donna Krasnewich; William A Gahl; Marinos C Dalakas Journal: Mol Genet Metab Date: 2004-03 Impact factor: 4.797
Authors: Xiaohua Wu; Richard A Steet; Ognian Bohorov; Jaap Bakker; John Newell; Monty Krieger; Leo Spaapen; Stuart Kornfeld; Hudson H Freeze Journal: Nat Med Date: 2004-04-25 Impact factor: 53.440
Authors: Yiumo Michael Chan; Paul Lee; Steve Jungles; Gabrielle Morris; Jaclyn Cadaoas; Alison Skrinar; Michel Vellard; Emil Kakkis Journal: PLoS One Date: 2017-03-07 Impact factor: 3.240
Authors: Sandra Brasil; Carlota Pascoal; Rita Francisco; Dorinda Marques-da-Silva; Giuseppina Andreotti; Paula A Videira; Eva Morava; Jaak Jaeken; Vanessa Dos Reis Ferreira Journal: Int J Mol Sci Date: 2018-04-27 Impact factor: 5.923